Drugs / 211At-BC8-B10
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03670966 | Jul 2019 → Jan 2028 expected | acute lymphoblastic leukemia, chronic myelomonocytic leukemia, mixed phenotype acute leukemia, myelodysplastic syndrome with excess blasts | Fred Hutchinson Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 211At-BC8-B10 | “A Phase I/II Study Evaluating Escalating Doses of 211At-Labeled Anti-CD45 MAb BC8-B10 (211At-BC8-B10) Followed by Related Haplo-Identical Allogeneic Hematopoietic Cell Transplantation” NCT03670966 ↗ |
| Known as | APAMISTAMAB-B10-ASTATINE AT-211 | “APAMISTAMAB-B10-ASTATINE AT-211” NCT03670966 ↗ |
| Modality | Monoclonal antibody | “211At-BC8-B10 is a monoclonal antibody” NCT03670966 ↗ |
| Route | Other | “astatine At 211 anti-CD45 monoclonal antibody BC8-B10 infusion over 6-8 hours on day -8” NCT03670966 ↗ |